Table 1. Patient demographics and clinical characteristics stratified according to Metavir F stages (F0-F4).

	Metavir F0		Metavir F1		Metavir F2		Metavir F3		Metavir F4		ANOVA
Parameters	n	Mean [95% CI] or n (%)	n	Mean [95% CI] or n (%)	n	Mean [95% CI] or n (%)	n	Mean [95% CI] or n (%)	n	Mean [95% CI] or n (%)	p-value
Male sex	31	60%	99	60%	80	68%	36	73%	27	69%	0.113
Age, yr	52	36.9 [34.1–39.6]	175	41.4 [39.8–42.9]	117	44.3 [42.7–45.8]	49	47.1 [44.4–49.8]	39	48.8[46.6–51.1]	<0.001
BMI (kg/m 2 )	51	26.3 [24.9–27.7]	167	26.1 [25.3–26.9]	105	27.8 [26.7–28.9]	47	28.3 [27.0–29.6]	36	27.1 [25.7–28.4]	0.020
AST (IU/L)	46	52.0 [42.0–62.1]	164	68.6 [60.9–76.3]	108	81.0[71.6–90.4]	47	115.9[95.0–136.9]	34	129.2 [107.0–151.4]	<0.001
ALT (IU/L)	46	80.4 [59.1–101.7]	164	98.2 [85.3–111.1]	108	116.9 [98.9–134.9]	47	152.6 [122.2–183.]	34	147.4[116.0–178.7]	<0.001
ALP (IU/L)	46	81.4 [74.3–88.5]	164	79.7[75.7–83.7]	108	81.4 [77.1–85.6]	47	98.8 [88.9–108.7]	34	98.0 [86.0–110.0]	<0.001
Albumin (IU/L)	46	43.1 [42.2–44.0]	164	43.5 [43.1–43.9]	108	43.1 [42.5–43.7]	47	42.9 [42.2–43.7]	34	40.6 [39.1–42.2]	<0.001
Bilirubin (μmol/L)	46	10.8 [9.3–12.4]	164	11.4 [10.5–12.2]	108	10.9 [10.0–11.8]	47	13.0 [11.4–14.6]	34	15.3 [12.9–17.7]	0.001
gGT (IU/L)	46	58.5 [42.0–75.0]	164	69.5 [54.0–85.1]	108	83.1 [67.8–98.3]	47	124.7 [95.8–153.7]	34	117.5 [90.9–144.1]	<0.001
Creatinine (μmol/L)	30	78.6 [71.6–85.7]	103	77.3 [74.5–80.1]	87	75.5 [72.3–78.7]	38	73.4 [69.4–77.3]	27	73.3 [68.2–78.4]	0.473
INR	48	0.931 [0.907–0.955]	165	0.965 [0.954–0.976]	105	0.955 [0.943–0.968]	48	0.996 [0.977–1.015]	33	1.06 [1.02–1.09]	<0.001

CI, Confidence Interval; BMI, Body Mass Index; AST, Aspartate Transaminase; ALT, Alanine Transaminase; ALP, Alkaline Phosphatase; gGT, Gamma Glutamyltransferase; INR, International Normalized Ratio; n, number of observations; ANOVA, One-way analysis of variance.